Dutch Biotech Argenx Claims $1.8Bn Licensing Deal With J&J
Argenx Of The Netherlands Has Licensed A Drug For Blood Cancers To Johnson & Johnson In A Deal That Gives It A Hefty $300M Upfront Payment, Plus A $200M Equity Investment By The Big Pharma Company.The Deal Centres On Cusatuzumab (Argx-110), A Cd70-Targeting Antibody That Is Being Developed For The Treatment Of Acute Myeloid Leukaemia (Aml), Myelodysplastic Syndrome (Mds) And Other Haematological Cancers And Is In Phase 1/2 Testing. It Also Covers Next-Generation Anti-Cd70 Drugs.All Told, Milestone Payments Of $1.3Bn Could Swell J&J
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
